Skip to content
Back to SPTX

Seaport Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
3
Purchases
3
Sales
0
Purchase value
$20.14M
Sale value
$0.00

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Denice TorresDirector
4
Filed Nov 4, 2026Period of report Nov 3, 20260001193125-26-446216
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseNov 3, 2026
Common Stock5,000$19.865$99.33K5,000Direct
Filing footnotes · 1
  1. F1The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open on SEC EDGAR
Robert J. HombachDirector
4
Filed Jun 24, 2026Period of report Jun 22, 20260001193125-26-280175
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseJun 22, 2026
Common StockF1F213,000$18.136$235.77K13,000IndirectBy Robert Joseph Hombach Revocable Trust
Filing footnotes · 2
  1. F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.65 to $18.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  2. F2The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open on SEC EDGAR
ARCH Venture Fund XII, L.P.10% owner
ARCH Venture Partners XII, LLC10% owner
ARCH Venture Partners XII, L.P.10% owner
Burow Kristina10% owner
Crandell Keith10% owner
Gillis Steven10% owner
Nelsen Robert10% owner
4
Filed May 4, 2026Period of report May 4, 20260001193125-26-204458
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMay 4, 2026
Common StockF21,100,000$18.00$19.80M6,294,951IndirectBy ARCH Venture Fund XII, L.P.
Filing footnotes · 2
  1. F1Each share of Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  2. F2Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.